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Analysis of the plasminogen activator activity of the human glomerulus.
An assay was developed to measure plasminogen activator activity
from isolated human glomeruli. Activator was extracted from individual
glomeruli with 0.2 si phosphate-buffered saline, pH 7.4 (PBS), contain-
ing 0.01% Triton X-lOO and quantitated in '251-fibrin films. Quenching
studies using antibodies to tissue plasminogen activator and urokinase
revealed that the extracted glomerular plasminogen activator activity
contained both tissue plasminogen activator and urokinase. Monoclonal
and polyclonal antibodies raised to tissue plasminogen activator dem-
onstrated low-level inhibition of urokinase activity and monoclonal and
polyclonal antibodies to urokinase demonstrated low-level inhibition of
tissue plasminogen activator activity. The assay should be applicable to
the study of glomerular plasminogen activator activity in experimental
and human kidney diseases. The detection of antibody cross-reactivity
to tissue plasminogen activator and urokinase may be related to the
sensitivity of the '251-fibrin film assay and to the structural similarities of
these activators.
Fibrinolysis means dissolution of a solid fibrin thrombus and
is mediated by an enzyme system having three major compo-
nents: 1) a circulating inactive proenzyme (plasminogen) which
can be activated to the fibrinolytic enzyme plasmin, 2) activa-
tors of plasminogen and, 3) inhibitors of plasmin and/or plas-
minogen activators [1]. Two types of plasminogen activator
have been defined in man, tissue plasminogen activator (TPA)
and urokinase (UK) [2]. Whereas the former was originally
associated with vessel walls and the latter was initially found in
the urine, both types of activator have now been detected in
several cell lines, including endothelial cells [3]
Plasminogen activator activity has been found in human
glomeruli [4—8] and reduced activator activity may play a role in
the pathogenesis of certain disease states such as renal homo-
graft rejection [7—9] and the hemolytic uremic syndrome [101. In
the present study, we have developed techniques to extract and
measure plasminogen activator from isolated human glomeruli
and have applied these methods to study the nature of the
glomerular plasminogen activator activity.
Methods
Bovine fibrinogen was obtained from Miles Laboratories,
Elkhart, Indiana, USA; '25Nal from Amersham, Arlington
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Heights, Illinois, USA; Triton X-lOO from Sigma Chemical
Company, St. Louis, Missouri, USA; lysine-Sepharose 4B and
protein A-Sepharose from Pharmacia Fine Chemicals, Piscata-
way, New Jersey, USA; plasminogen-free human thrombin
(2800 NIH U/mI) from Dr. John W. Fenton II, New York State
Department of Health, Albany, New York, USA; 24 well,
polystyrene tissue culture, cluster plates from Costar, Cam-
bridge, Massachusetts, USA; and micro-tissue grinders from
Fisher Scientific Company, Cincinnato, Ohio, USA.
Human plasminogen was prepared from outdated human
plasma by the method of Deutsch and Mertz and was treated
with phenyl-methyl-sulfonyl-fluoride to remove traces of plas-
mm activity [11]. Standard urokinase was from the National
Heart, Lung, and Blood Institute, National Institutes of Health.
Low (33,000) and high (54,000) molecular weight urokinase was
purchased from Calbiochem, San Diego, California, USA.
Tissue plasminogen activator was purified [12] from an estab-
lished human melanoma cell line (Bowes) obtained from Dr.
Daniel Riflin, Rockefeller University. Single-chain tissue plas-
minogen activator was purchased from American Diagnostica,
Greenwich, Connecticut, USA. Antisera against tissue plasmin-
ogen activator were raised in rabbits who received subcutane-
ous injections of the antigen emulsified with complete Freund's
adjuvant. Three weeks later, booster injections of the antigen
emulsified with incomplete Freund's adjuvant were given into
the footpads. Rabbit serum was obtained two weeks after the
booster injections and the lgG fraction was isolated by affinity
chromatography on protein A-Sepharose [13]. Rabbit antibody
specific for urokinase [14] was from Rockefeller University; the
antibody was purified by protein A-Sepharose and urokinase-
Sepharose 4B chromatography. Mouse monoclonal antibodies
to tissue plasminogen activator and urokinase were obtained
from Monozyme, Lyngby, Denmark. Purified rabbit antibody
specific for human alpha2-macroglobulin (2—MAC) was pur-
chased from Accurate Chemical and Scientific Company, West-
bury, New York, USA.
Normal human renal cortex was obtained at the time of
nephrectomy from the normal pole of kidneys removed because
of an opposite pole tumor. The specimens, which were later
shown to be histologically normal, were immediately cut into 2
x 4 mm portions, snap-frozen in isopentane precooled in liquid
nitrogen, and stored at —70°C until studied.
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Measurement of glomerular plasminogen activator activity
A modification of the '251-labeled fibrin film technique [IS]
was developed to measure glomerular plasminogen activator
activity. Bovine fibrinogen was freed from contaminating plas-
minogen by passage through lysine-Sepharose 4B and then
iodinated with 25j by the iodine monochloride method [16].
1251-fibrinogen (0.2 ml), diluted with unlabeled fibrinogen in
PBS, was added to each well (0.024 mg of fibrinogen per well)
of the Costar plate, yielding approximately 50,000 cpm per well.
The plates were dried overnight at room temperature and then
converted to fibrin by the addition of 0.2 ml (0,04 tg) of
thrombin per well. After incubation with thrombin for two
hours at 37°C in a moist environment, each well was washed
three times with PBS. Prior to use, each well was again washed
twice with PBS. The plasminogen activator activity of glomer-
ular extracts was determined by measuring the radioactivity
released after appropriate (Results) incubation of the reaction
mixture which contained the extract to be tested in 0.5 ml of
buffer and 10 pi (4.0 tg) of human plasminogen. After incuba-
tion in a moist chamber at 37°C, the radioactivity released into
0.3 ml of the reaction mixture was counted in a gamma
spectrometer. All plates contained controls for background
radioactivity release and non-specific proteolytic activity by
including wells containing buffer with and without plasminogen
and tissue plasminogen activator and glomerular extract with-
out plasminogen.
Isolation of individual glomeruli
The tissue to be studied was placed in a disposable plastic
Petri dish and thawed at room temperature. One drop of
isotonic saline was added to the tissue and the dish was then
placed under a dissecting microscope at 30 x magnification.
Using two 26 gauge needles attached to I ml tuberculin sy-
ringes, the tissue was gently teased apart until the glomeruli
popped out. The glomeruli were easily identified by their
mulberry shape, appearing darker than the surrounding tissue.
The isolated glomeruli were aspirated by capillary action into a
5 ,ui pipette and transferred to the appropriate container for
extraction of plasminogen activator.
Extraction of glomerular plasminogen activator
The following buffer systems [17—19] were utilized to extract
glomerular plasminogen activator:
Buffer System I.
I. Extract with 0.5% Triton X-lOO in water.
2. Centrifuge at 1000 X g for 5 mm.
3. Acidify to pH 3 with 0.05 M glycine buffer, pH 2.7.
4. Incubate for 60 mm at 37°C.
5. Reconstitute to pH 7.4 with 0.1 volume of I M Tris-HCI, pH
8.1.
Buffer System 2. 0.3 M potassium acetate, pH 4.2.
Buffer System 3. PBS.
All buffers contained 0.01% Triton X-l00 to prevent activator
adsorption to surfaces. A buffer commonly used to extract
plasminogen activator [201,2 MKSCN, was eliminated from the
study when found to inhibit fibrinolysis in the '25I-fibrin films.
In certain studies, the isolated glomeruli were placed in
micro-tissue grinders containing buffer and were ground at
room temperature for 15 minutes prior to extraction.
Activator inhibition studies
To evaluate the nature of the glomerular plasminogen activa-
tor activity, glomerular extracts (in 0.5 ml PBS) from seven
normal human kidneys were incubated with increasing volumes
(25, 50, 75, 100, and 150 d) of antibodies specific for tissue
plasminogen activator, urokinase, or alpha2-macroglobulin (con-
trol), as well as PBS. Three glomeruli from each kidney were
studied individually on two separate occasions. The protein
concentration of each antiserum was 0.7 mg/mI. In each exper-
iment, the extract of glomerular activator was incubated with
antibody or PBS at 37°C for two hours. After incubation, the
mixture was centrifuged at 5000 x g for 30 minutes and the
supernate was studied with the '251-fibrin film assay. The results
of the antibody studies are expressed as the percent reduction
of the radioactivity released by the extract containing an
equivalent volume of PBS in place of the antibody.
To determine the inhibitory activity of the antibodies to tissue
plasminogen activator and urokinase for the alternative activa-
tor, 8,000 x 10—6 IU (World Health Organization) of tissue
plasminogen activator and 1,600 x 10_6 IU of urokinase in 0.5
ml PBS (the amounts of tissue plasminogen activator and
urokinase selected were those that released 10,000 cpm) were
incubated with 25, 50, 75, 100, and 150 d of each antibody at
37°C for two hours. The mixture was then centrifuged at 5000 x
g for 30 minutes and the supernate was studied by the '25I-fibrin
film assay. In each experiment, an equivalent volume of PBS
was substituted for each antibody to determine the amount of
radioactivity released by the activator in the absence of anti-
body. The results are expressed as the percent reduction by the
antibody of the radioactivity released by the reaction mixture
when PBS was substituted for the volume of antibody.
Fibrin auto graphy
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed as described by Laemmli [211.
Seventy glomeruli from a single normal kidney were isolated
and extracted in 0.5 ml PBS for one hour at 37°C; the mixture
was then centrifuged at 5000 x g for 30 minutes. Slab gel
electrophoresis was performed with resolving gels of 10% and
stacking gels of 5% acrylamide. Glomerular extract (0.1 ml) was
applied to the gels which were then subjected to electrophoresis
at 15 mamp per gel at room temperature until the dye front
reached the end of the gel. Tube gel electrophoresis was
performed with resolving gels of' 7% and stacking gels of 3%
acrylamide. Glomerular extract (0.15 ml) was applied to the gels
which were then subjected to electrophoresis at 5 mamp per gel
until the dye front reached the end of the gel. As a positive
control, all studies included gels to which urokinase (250,000 x
106 lU/mi) was applied in a volume equal to the glomerular
extract. Certain gels were fixed with 50% trichloroacetic acid,
stained with 1% Coomassie Blue, and then destained in 10%
acetic acid while others were utilized for fibrin autography.
Fibrin autography was performed by the method of Granelli-
Piperno and Reich [22] using fibrin-agar indicator films pro-
duced by mixing 2% agarose at 45°C with pre-warmed PBS
containing plasminogen (25 tgIml) and thrombin (0.6 U/mI).
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Bovine fibrinogen (10 mg/mI) in PBS (37°C) was added and the
mixture was poured onto a plastic plate. After electrophoresis,
the SDS gels were immersed in 2.5% Triton X-i0O (two changes,
45 mm each), patted dry with a paper towel, applied to the
surface of the fibrin-agar indicator film, and then incubated at
37°C in a moist chamber for up to 72 hours.
Analysis of data
Because the polyclonal antibody studies had two complete
replications of the 30 combinations of two antigens, three
antisera, and five volumes of antisera, a complete four-way
factional analysis of variance was carried out using the SAS
packge of statistical analysis programs [23]. The mean squares
for the seven interactions involving the replications factor were
found to be satisfactorily homogeneous by Bartlett chi-square
test [24] and were accordingly pooled into a single error mean
square with 29 degrees of freedom. Tests between pionts on the
percent reduction of radioactivity released curves were then
carried out using Student (-tests based on this pooled error
mean square.
As the monoclonal antibody studies were not replicated due
to insufficient antibody, the observations from the single run
were analyzed by a three-way analysis of variance and the mean
square for the highest order interaction (8 degrees of freedom)
used as error variance to construct (-tests between points on the
percent reduction curve as above.
Results
Deve/optnent and evaluation of the activator assay
Determination of the optimum buffer system fr activator
extraction. Three sets of two glomeruli (triplicate studies) from
0 u
7.0 7.2 7.4 7.6 7.8 8.0 8.2
pH of PBS
Fig. 2. lft'ct of varying i/ic pH of PBS on activator extraction.
the same portion of renal cortex were extracted in each buffer
for two hours at 37°C. The extract was centrifuged, incubated in
the '251-fibrin films for 18 hours at 37°C. and the fluid in the wells
was then counted in a gamma spectrometer. The mean value
and range of the counts per minute for each buffer are depicted
in Figure 1 and demonstrate that buffer system 3 (PBS) is the
optimum buffer for activator extraction. Interestingly, when
similar studies were performed after grinding the glomeruli,
PBS was again found to be the best buffer (data not shown)
although the total number of counts released with each buffer
was less than that obtained after simple extraction. Presumably,
grinding the glomeruli releases both activator and activator
inhibitor. Therefore, all subsequent studies utilized PBS as the
buffer and grinding was omitted.
Variation in buffer pH. To determine the optimum pH for
activator extraction, pairs of glomeruli from a single kidney
were extracted in PBS having a pH ranging from 7.0 to 8.2, The
results (Fig. 2) confirm that maximum extraction occurs at pH
7.4.
Variation in extraction time and temperature. To evaluate
the optimum duration and temperature for activator extraction,
pairs of glomeruli from the same kidney were incubated in PBS
for 10, 20, 40, 60, 90, and 120 minutes; separate studies were
performed at 4, 23, and 37°C. The results (Fig. 3) confirm that
incubation for 60 minutes at 37°C is optimal for activator
extraction.
Variation in number of glomneruli extracted. To determine the
minimum number of glomeruli required for reliable extraction,
I to 10 glomeruli were extracted with PBS. Extraction of one
glomerulus from the same kidney on five separate occasions
yielded an average of 25,493 cpm (range 22,860 to 27,315).
Thus, extraction of a single glomerulus yielded adequate acti-
vator (release of approximately 50% of total radioactivity in the
well) for analysis with an assay variation of 10%.
Variation in '251-fibrin fl/mn incubation ti/ne. To detect the
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Fig. 4. Effect of varying the reaction mLture incubation time in the
'251-fibrin fi!,ns on release of radioactivity (fihrino!vsis).
optimum time to incubate the reaction mixture in the '251-fibrin
film to permit adequate release of radioactivity (fibrinolysis),
experiments were performed using both extracted glomerular
plasminogen activator and purified tissue plasminogen activator
(2000 x lO_6 IU). The mean values for release of radioactivity
from eight experiments are depicted in Figure 4 and confirm
that seven hours is a satisfatory incubation time.
Final activator assay. From the above studies, our assay of
glomerular plasminogen activator activity consisted of extrac-
tion of three individual glomeruli in 0.5 ml PBS for 60 minutes
at 37°C. After centrifugation at 5000 x g for 30 minutes, the
reaction mixture (glomerular extract plus plasminogen) was
incubated in the '251-fibrin films for seven hours. Following
incubation, 0.3 ml is removed from each well and counted in a
gamma spectrometer. For each kidney studied, the activator
activity was expressed (% release of total radioactivity in the
well) as the average value of the three glomeruli studied as long
as the variation between the values was less than 10%. if this
variation exceeded 10%, then the experiment was repeated.
The sensitivity of the assay was determined by creating
standard curves for tissue plasminogen activator and urokinase.
In comparison to background release of radioactivity, the assay
was capable of detecting 125 x 10-6 IU of tissue plasminogen
activator and 50 x l0_6 IU of urokinase. Release of 50% of the
total radioactivity occurred with 4000 x 10_6 IU of tissue
plasminogen activator and 800 x 10_6 IU of urokinase. Release
of 100% of the total radioactivity in the wells occurred with
16,000 x 10—6 IU of tissue plasminogen activator and 6400 x
10-6 IU of urokinase.
That the assay specifically detects plasminogen activator
activity rather than nonspecific proteolytic activity was con-
firmed by removing plasminogen from the reaction mixture. In
the absence of plasminogen, neither tissue plasminogen activa-
tor nor glomerular extract released more radioactivity than that
obtained from wells containing PBS alone.
Characterization of glom era/ar plasminogen activator activity
Incubation of glomerular extract from seven normal human
kidneys with polyclonal or monoclonal antibodies to tissue
plasminogen activator and urokinase resulted in similar reduc-
tions in plasminogen activator activity (Fig. 5). A consistent low
level of activator inhibition was seen following incubation of the
glomerular extracts with the control antibody to alpha2-macro-
globulin.
Staining of the SDS gels containing glomerular extract after
electrophoresis revealed no protein bands and no fibrinolytic
activity was detected by fibrin autography after 72 hours
incubation. Control gels containing urokinase readily demon-
strated fibrinolytic activity within 24 hours. This suggests that
fibrin autography, even after an extended incubation, is not
sufficiently sensitive to detect the low levels of glomerular
activator that may remain in the SDS gels following electropho-
resis.
Evaluation of antibody cross-reactivity
That antibodies to both plasminogen activators reduced the
plasminogen activator activity of glomerular extracts more than
60% suggested the possibility of cross-reactivity between the
activators and the antibodies. This was confirmed when tissue
plasminogen activator and urokinase were incubated with mo-
noconal and polyclonal antibodies to both activators; anti-
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Fig. 6. Effect of adding increasing volumes o.fpolyclonal antibody
against tissue plasminogen activator (TPA), urokinase (UK), and
alpha2-macroglohu!in (a2-MAC) to 8000 x 10-6 JU of tissue plasmino-
gen activator and 1600 x 10 IV of standard urokinase. The results
are expressed as the % reduction by the antibody of the radioactivity
released when PBS was substituted for the antibody. Similar results
(not shown) were obtained using monoclonal antibody to each activa-
tor. (A) 0.01 < P < 0.05 and (•) P < 0.01 in comparison to
anti-alpha2-macroglobulin control value.
alpha2-macroglobulin served as a control. Maximum inhibition
of tissue plasminogen activator and standard urokinase activity
was detected after incubation with specific polyclonal or mono-
clonal antibody (Fig. 6). A significant (P < 0.01) reduction in
activity in comparison to control alpha2-macroglobulin anti-
body was noted when antibody volumes exceeded 50 .d.
However, significant (P < 0.01) inhibition of activator activity
beyond that detected with control antibody was also seen after
incubation with 150 pi of the alternative antibody.
Analogous results were obtained when monoclonal and poly-
clonal antibodies to tissue plasminogen activator and urokinase
were incubated with high and low molecular weight urokinase
(Fig. 7). Significant (P < 0.01) inhibition of both high and low
molecular weight urokinase was observed when the volume of
antibody to urokinase exceeded 50 /Ll. Inhibition (P < 0.01) of
high molecular weight urokinase was noted when the volume of
antibody to tissue plasminogen activator exceeded 50 l, and
inhibition (P < 0.01) of low molecular weight urokinase was
found when the volume of this antibody exceeded 75 pJ.
Similarily, incubation of single-chain tissue plasminogen ac-
tivator with monoclonal and polyclonal antibodies to tissue
plasminogen activator resulted in significant (P < 0.01) inhibi-
tion of activity when antibody volumes exceeded 25 d (Fig. 8).
Monoclonal antibody to urokinase significantly inhibited single-
chain tissue plasminogen activator in volumes exceeding 25 pi
and polyclonal antibody to urokinase inhibited the single-chain
activator in volumes exceeding 75 .tl.
In each antibody study, non-specific proteolytic activity was
absent in control wells containing antibody and PBS with and
without plasminogen.
Discussion
The fibrin slide technique, a histochemical method of fibrino-
lysis autography, has previously been utilized to demonstrate
glomerular plasminogen activator activity [4—8]. However, that
technique lacks the precision required to specifically analyze
glomerular plasminogen activator activity, and its results may
be obscured by fibrinolytic activity emanating from non-glome-
rular structures. The techniques reported in this study allow
quantitation of plasminogen activator activity of individual
glomeruli and should be applicable to the study of this activity
in experimental and human kidney diseases.
Using these techniques, we have found that the plasminogen
activator activity of the human glomerulus derives from both
tissue plasminogen activator and urokinase, confirming the
studies of Angles-Cano and associates [25]. However, the
source of these plasminogen activators remains to be deter-
mined. A likely candidate would be the glomerular endothelial
cell. Plasminogen activator activity has been found in rabbit
[18, 26], rat [17], and bovine [27—29] endothelial cells, and the
latter have been found to produce activators resembling both
tissue plasminogen activator and urokinase [3. 30, 31].
Although studies by other investigators have suggested that
tissue plasminogen activator and urokinase are immunologi-
cally distinct and that antibodies raised against one activator fail
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to inhibit the activity of the other [12, 31—34], our studies
suggest that antibodies to one activator may inhibit, to a lesser
degree, the activity of the alternative activator. It seems un-
likely that these unique findings could be related to contamina-
tion of the prinipal antigen with small amounts of the other
activator because of the careful methods of activator prepara-
tion [12, 14] and the lack of evidence that the melanoma cell line
can produce urokinase [12]. To enhance the specificity of the
urokinase antibody, it was immunopurifled by urokinase-Seph-
arose chromatography which should remove contaminating
antibody to tissue plasminogen activator. Unfortunately, we
lack sufficient tissue plasminogen activator to purify the anti-
body to tissue plasminogen activator in a similar manner.
Although absorption of each antibody with the alternate acti-
vator might improve antibody specificity, it could, of course,
also remove evidence of antibody cross-reactivity.
The failure of other investigators to detect the inhibitory
activity of anti-urokinase on tissue plasminogen activator and
anti-tissue plasminogen activator on urokinase may be related
to the use of caseinolytic, standard fibrin plate, and fibrin slide
assays which seem less sensitive than the '251-fibrin film assay
used in this study. The cross-reactivity of the antibodies against
the activators may be related to the structural similarities of
these two serine protease enzymes [35, 36] which may have
evolved from a common ancestral gene [36—38]. Indeed, Taka-
hashi and Naora have recently produced a monoclonal antibody
to the active site of urokinase that recognizes the active site of
tissue plasminogen activator and have demonstrated a high
degree of homology between their entire amino acid sequences
[391.
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